SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and patients, today reported data from its pivotal ...

The acquisition will allow Intersect ENT’s portfolio to support routine and complex procedures and positions the company to serve the growing market for ENT services, the statement said. It will also ...

On May 13, 2022, Medtronic, Inc. announced that it completed the acquisition of Intersect ENT, Inc. The transaction was only able to gain approval of the Federal Trade Commission (FTC) upon the ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported ...

Staying true to its pledge to crack down on potentially anticompetitive megamergers in the healthcare industry, the U.S. Federal Trade Commission has ordered Medtronic and Intersect ENT to adjust the ...

Intersect ENT XENT reported first-quarter 2022 GAAP loss per share of 85 cents, wider than the year-ago adjusted loss of 61 cents. The figure was also wider than the year-ago adjusted loss of 34 cents ...

It may have taken an order from the Federal Trade Commission to get there—and Medtronic may be getting less bang for its buck than initially expected—but the medtech giant’s acquisition of Intersect ...

Medtronic said Friday that it has closed on a deal to acquire California-based Intersect ENT, one day after the Federal Trade Commission said the acquisition could move forward only if Medtronic ...

Intersect ENT has announced it has received FDA approval of the company’s second steroid-releasing product, according to a news release (pdf). The PROPEL mini is designed for localized drug delivery ...

Intersect ENT Inc. XENT reported third-quarter 2021 adjusted loss per share of 48 cents, wider than the Zacks Consensus Estimate of a loss of 42 cents. The figure was also wider than the year-ago ...